Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis | Zendy

Srđan Verstovšek | Zendy; Hagop M. Kantarjian | Zendy; Ruben A. Mesa | Zendy; Animesh Pardanani | Zendy; Jorge E. Cortés | Zendy; Deborah A. Thomas | Zendy; Zeev Estrov | Zendy; Jordan S. Fridman | Zendy; Edward C. Bradley | Zendy; Susan EricksonViitanen | Zendy; Kris Vaddi | Zendy; Richard Levy | Zendy; Ayalew Tefferi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

Author(s) -

Srđan Verstovšek,

Hagop M. Kantarjian,

Ruben A. Mesa,

Animesh Pardanani,

Jorge E. Cortés,

Deborah A. Thomas,

Zeev Estrov,

Jordan S. Fridman,

Edward C. Bradley,

Susan EricksonViitanen,

Kris Vaddi,

Richard Levy,

Ayalew Tefferi

Publication year - 2010

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1002028

Subject(s) - myelofibrosis , ruxolitinib , medicine , janus kinase 2 , myeloproliferative neoplasm , myeloproliferative disorders , janus kinase , gain of function , kinase , mutation , cancer research , oncology , gene , bone marrow , genetics , biology , receptor

Myelofibrosis is a Philadelphia chromosome–negative myeloproliferative neoplasm associated with cytopenias, splenomegaly, poor quality of life, and shortened survival. About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiology of the disease. INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research